Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and tauopathies have long been associated with genetic risk factors, but a new study published in Molecular Psychiatry by Dr. John Hardy and Dr. Valentina Escott-Price offers a fresh perspective. Instead of viewing these diseases as being “caused” by specific genetic mutations, the study reframes them as conditions that arise from age-related failures in the body’s ability to clear damaged proteins. This insight shifts the focus toward enhancing clearance mechanisms as a therapeutic strategy for neurodegeneration.
Ageing, Protein Clearance, and Disease Risk
Genetic studies have traditionally sought mutations that directly cause neurodegenerative diseases. Still, genome-wide association studies (GWAS) now suggest that most risk factors are related to failures in cellular cleanup processes rather than the production of toxic proteins themselves.
Alzheimer’s Disease (AD):
The central pathology involves amyloid-beta (Aβ) plaques typically cleared by microglia. Many AD risk genes are linked to microglial function and lipid metabolism, suggesting that genetic variations contribute to reduced clearance efficiency rather than excessive Aβ production.
Parkinson’s Disease (PD):
Mutations in genes associated with lysosomal function (GBA, LRRK2) disrupt the clearance of alpha-synuclein, leading to its toxic accumulation in Lewy bodies.
Tauopathies (e.g., Frontotemporal Dementia, Progressive Supranuclear Palsy):
These diseases involve the buildup of tau protein, which is normally removed by the ubiquitin-proteasome system. Variants affecting this pathway increase the risk of tau accumulation and neuronal dysfunction.
Dr. Hardy and Dr. Escott-Price argue that these conditions should not be seen as being caused by genetic “mistakes,” but rather as the result of normal clearance mechanisms becoming overwhelmed with age.
Why Neurodegeneration Happens Later in Life
A key question in neurodegeneration research has always been: if genetic risk factors are present from birth, why do these diseases primarily develop in older adults? The authors provide a compelling answer—while clearance systems work effectively in youth, their efficiency naturally declines with age.
1. Aging Microglia & Lysosomal Dysfunction: Over time, microglia become less effective at clearing Aβ, while lysosomes lose their ability to break down alpha-synuclein.
2. Increased Protein Load: Aging cells accumulate more damaged proteins, further straining clearance mechanisms.
3. Systemic Inflammation & Metabolic Changes: Age-related changes in immune function and metabolism can disrupt protein clearance pathways, leading to increased neurodegenerative burden.
This perspective helps explain why seemingly “protective” genes, such as those involved in lysosomal function, still fail to prevent disease in older adults—clearance simply can’t keep up with damage accumulation.
Co-Pathologies: Why Most Brains Show Mixed Diseases
One of the most striking findings in ageing and neurodegeneration research is that most elderly individuals do not develop just one neurodegenerative pathology. Instead, brain autopsies often reveal a mix of Alzheimer’s, Parkinson’s, and vascular disease-related changes.
Hardy and Escott-Price suggest that rather than these pathologies being entirely separate, they may share an underlying cause: interconnected clearance failures.
• When the microglial system is overwhelmed with Aβ, it may not be able to handle tau pathology effectively.
• Lysosomal dysfunction that impairs alpha-synuclein clearance in Parkinson’s may also contribute to tau accumulation in some cases.
• Vascular disease, common in aging, further compromises clearance mechanisms by reducing blood flow and nutrient supply to the brain.
This interconnection has important implications: rather than treating neurodegenerative diseases in isolation, therapies should focus on strengthening clearance systems across multiple pathways.
Rethinking Genetic Risk and Disease Prediction
With a new understanding of how clearance failure drives neurodegeneration, the study suggests refining how we assess genetic risk.
• Polygenic Risk Scores (PRS): Traditional PRS models assume a static risk over a person’s lifetime, but Hardy and Escott-Price argue that these should be age-adjusted. A person with high-risk variants may remain symptom-free for decades if their clearance systems hold up, whereas someone with only moderate risk factors might develop disease earlier if their clearance pathways decline more rapidly.
• Age-Specific Genetic Analyses: GWAS studies should analyze genetic risk at different ages rather than treating all cases as a single group. For example, the genetic contributors to Alzheimer’s in a 65-year-old may differ from those in a 90-year-old, where co-pathologies play a bigger role.
The Path Forward: Enhancing Clearance as a Treatment Strategy
If neurodegeneration is primarily a problem of failing clearance, then therapies should aim to restore these systems rather than just targeting toxic protein accumulation. Some promising avenues include:
• Microglial Activation Modulation: Drugs that enhance microglial function without triggering excessive inflammation may improve Aβ and tau clearance.
• Lysosomal & Autophagy Boosters: Strategies to enhance lysosomal function (e.g., GBA activators in Parkinson’s) could help prevent alpha-synuclein buildup.
• Blood-Brain Barrier Support: Maintaining vascular health may indirectly support clearance pathways by ensuring an adequate supply of nutrients and oxygen.
By shifting focus toward keeping clearance pathways functional as we age, researchers may be able to delay or even prevent neurodegenerative diseases before they take hold.
The study by Hardy and Escott-Price reframes the genetics of neurodegenerative diseases not as a matter of “faulty genes” but as a progressive decline in damage clearance mechanisms. This shift in perspective has profound implications for how we study, predict, and treat Alzheimer’s, Parkinson’s, and related conditions.
Instead of focusing solely on blocking toxic protein formation, therapies should aim to enhance clearance mechanisms, ensuring that the brain can continue managing protein homeostasis well into old age. If successful, such an approach could lead to a new era of neurodegeneration prevention, helping millions maintain cognitive health for longer.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
